Dr. Michael Har-Noy, CEO of Immunovative Therapies, Ltd., says that chaperone-rich cell lysate (CRCL), which is made up of heat shock proteins, has been used to produce tumor-specific immunity against many murine cancers. Dr. Michael Har-Noy notes that scientists have described ovarian tumor-derived CRCL's ability to activate dendritic cells promote tumor-specific T-cell production.
CRCL was made from SKOV3-A2 ovarian tumor cells. Dr. Michael Har-Noy says that dendritic cells with ovarian cancer-derived CRCL were used weekly to stimulate peripheral mononucleocytes from both HLA-A2+ donors and HLA-A2+ ovarian cancer patients. Cytotoxicity and cytokine production were subsequently measured after four to six treatments.
Dr. Michael Har-Noy noted that CRCL stimulation increased both the immune-stimulatory capacity of the dendritic cells as well as interleukin (IL)-12 production. T-cells from normal controls as well as from ovarian tumor patients secreted increased amounts of interferon-g after re-stimulation with CRCL as compared with dendritic cell stimulation.
Dr. Michael Har-Noy observed that without CRCL stimulation, investigators were able to produce cytotoxic T-lymphocyte activity against cancer specific antigens in all of healthy donors but in only one fourth of the ovarian cancer patients. Dr. Michael Har-Noy concludes that this substantiates the hypothesis that CRCL will effectively treat ovarian tumors and that this individualized vaccine will be a powerful new approach to cancer therapy.
Dr. Michael Har-Noy is now running a Phase I/II study of the CRCL vaccine in various solid malignancies. The study is being run in Bangkok, Thailand, and is combined with a Compassionate Use program.